Day1 Plenary Session

1
Day1 Plenary Session 
Lecture 1 Propagation of the neurodegenerative
process in PD and the Prion-like hypothesis
Lecture 2 Can the interaction between genetics,
environment, and behavior be a key determinant of
PD expression
Lecture 3 What epidemiological and preclinical
studies teach us about inflammation and PD
Lecture 4 Developing new treatments founded on
the basic science of PD
Special Lecture 1 The Life and Times of James
Parkinson
Special Lecture 2 The Glory of Canadian Sciences
and Parkinson's Disease
2
Day 2 Plenary Session 
Lecture 1 The spectrum of non-motor symptoms in
PD
Lecture 2 Dementia and psychiatric
manifestations in PD
Lecture 3 Contribution of functional
neuroimaging to the understanding of non-motor
manifestations of PD
Lecture 4 The impact of other medical conditions
on the course of PD
WPC James Parkinson Lecture Past, Present and
Future of Parkinsons Disease
3
Day 3 Plenary Session 
Lecture 1 Cell and gene-based technologies for
restorative and neuroprotective therapies
Lecture 2 Exercise, diet, and other lifestyle
activities as treatments for Parkinson disease
Lecture 3 Empowered patients and how they can
help improve healthcare
Lecture 4 Roles for healthcare professionals
multidisciplinary care for Parkinson disease.
Special Lecture Living Positively After a
Diagnosis of Parkinson's
4
Day 1 Parallel Session I
Parallel Session New genes and risk factors of PD
Lecture 1 New PD genes and rare variants
Lecture 2 Risk factors for sporadic PD
Lecture 3 Genetics and gene environment
interactions
Parallel Session Protein misfolding as a key
pathogenic event
Lecture 1 Alpha-synuclein conformation and
neurodegeneration
Lecture 2 Protein misfolding in
neurodegenerative diseases
Lecture 3 Link between lysosomal function and
neurodegeneration in PD
Parallel Session Role of functional imaging
modalities in the diagnosis and management of PD
Lecture 1 Structural imaging for PD MRI and
transcranial sonography (TCS)
Lecture 2 Neurochemical imaging
Lecture 3 Functional connectivity
Parallel Session Non-dopaminergic systems in PD
Anatomy, Biochemistry, and Pathology
Lecture 1 Role of noradrenaline and serotonin
systems for the development of non-motor symptoms
Lecture 2 Impact of cholinergic dysfunction on
the development of non-motor symptoms
Lecture 3 Role of non-dopaminergic systems in
the development of L-DOPA-induced dyskinesias
5
Day 1 Parallel Session I
Workshop 1 Why supporting research is crucial
from government to private funding agencies
Workshop 2 Mitochondrial defect in PD myth or
reality?
Workshop 3 Sexual issues in Parkinson's disease
assessment and intervention
Workshop 4 Quality of life and comfort in the
late stages of Parkinson's disease
6
Day 1 Parallel Session II
Parallel Session Quality of life in Parkinsons
disease several important determinants
Lecture 1 Practical solutions to driving, early
job loss, and relationship issues
Lecture 2 Psychological solutions to dealing
with pity, dignity, sense of worth and
communication
Lecture 3 Physical solutions to coping with
pain, motor/non-motor, cognition, mood, and
behavior
Parallel Session How Parkinsons affects
attention and memory
Lecture 1 Memory and attention issues in
Parkinsons diseaseclinical characteristics and
mechanisms
Lecture 2 Clinical Assessment of Cognition in PD
Lecture 3 Practical management of cognitive
deficits in Parkinson's disease what can
occupational therapists offer?
Parallel Session Experimental models of
non-motor manifestations of PD
Lecture 1 Animal models of hyper dopaminergic
behavior in Parkinsons disease
Lecture 2 Animal models of sleep disorders in
Parkinsons disease
Lecture 3 Animal models of gastrointestinal
dysfunction in Parkinsons disease
Parallel Session Optogenetic tools to study PD
pathophysiology
Lecture 1 Optical Neural Engineering
Lecture 2 Regulation of Parkinsonian motor
behaviors by optogenetic control of basal ganglia
circuitry
Lecture 3 Optical Interrogation of the
dopaminergic systems
7
Day 1 Parallel Session II
Workshop 1 Everything you always wanted to know
about genetics and that you never dared to ask
Workshop 2 How researchers and people with
Parkinsons can advance clinical trials together
Workshop 3 How drugs make it to your cabinet
Workshop 4 Music, art, creativity and
Parkinson's
8
Day 2 Parallel Session I
Parallel Session PD or not PD - that is the
question Is it time to redefine/reclassify
Parkinsons disease?
Lecture 1 Current definitions and diagnostic
criteria reasons for redefining the disorder.
Lecture 2 The challenge of "prodromal"
Parkinson's disease
Lecture 3 Redefining Parkinson's disease
possible approaches to developing new diagnostic
criteria
Parallel Session Hallucinations and related
phenomena in PD
Lecture 1 Prototypical and less common
hallucinations
Lecture 2 Where is the nucleus hallucinatorius
and how it gets stimulated?
Lecture 3 Management of hallucinations and
related symptoms
Parallel Session Mitochondrial quality control
mechanisms
Lecture 1 Mitochondrial quality control- a
matter of life and death for neurons
Lecture 2 Mechanisms of mitophagy in Parkinsons
disease
Lecture 3 Mitochondrial remodeling in the
control of apoptosis
Parallel Session Ways for people with
Parkinsons to become empowered
Lecture 1 Why and how people with Parkinsons
need empowerment - Finding your own niche
Lecture 2 Evidence-based self-management
practices
Lecture 3 Increasing Parkinsons advocacy
effectiveness with lessons learned from other
diseases
9
Day 2 Parallel Session I
Workshop 1 Benefits and risks of genetic testing
Workshop 2 Sleep and fatigue in PD
Workshop 3 Ethical dilemmas posed by new
diagnostic and therapeutic technologies
Workshop 4 Tricks of the trade clever
strategies to improve mobility
10
Day 2 Parallel Session II
Parallel Session PD or look-alikes how to
diagnose them and what are their long-term
prognoses?
Lecture 1 Drug Induced Parkinsonism
Lecture 2 PD or progressive supranuclear palsy
Lecture 3 PD or Multiple system atrophy
Parallel Session Clinical trial outcomesWhat do
they really mean?
Lecture 1 Clinical trial endpoints in PD What
is really meaningful?
Lecture 2 The placebo effect how it complicates
clinical trial results
Lecture 3 Slowing clinical progression in PD
can it be proven in clinical trials?
Parallel Session The search for new delivery
methods for drugs
Lecture 1 Improving oral drug delivery in PD
recent advances
Lecture 2 Infusion therapies and other non-oral
routes of drug delivery
Lecture 3 Delivering therapeutic genes into the
brain a future way of drug delivery?
Parallel Session Is PD an axonopathy?
Lecture 1 Pathological evidence for axonopathy
in Parkinsons disease
Lecture 2 Evidence for synaptic dysfunction in
Parkinsons disease
Lecture 3 Alterations in axonal transport in
Parkinsons disease
11
Day 2 Parallel Session II
Workshop Choosing a care facility When is it
time? What are the options?
Workshop Do experimental models of Parkinsons
disease predict treatment outcome?
Workshop Complementary and integrative medicine
Workshop Dance and Parkinsons Why and How?
12
Day 3 Parallel Session I
Parallel Session Update on Gaucher and
Parkinson's diseases
Lecture 1 What is new about the link between
Gaucher mutations and Parkinsonism
Lecture 2 Exploring mechanisms that underlie
between mutations in Gaucher disease gene and
synucleinopathy risk
Lecture 3 How the understanding of Gaucher could
lead to new therapies for Parkinson's
Parallel Session New insights into Parkinson's
disease from experimental cell- and gene-based
strategies
Lecture 1 Use of human ES and iPS cells for cell
replacement in Parkinsons disease
Lecture 2 Role of Sonic hedgehog in maintaining
striatal homeostasis
Lecture 3 Nurr1 as a therapeutic target for
neuroprotection and disease modification in PD
Parallel Session Neurobiology and treatment of
dyskinesias
Lecture 1 Maladaptive plasticity in
L-DOPA-induced dyskinesia emerging role of
serotonin transmission and other presynaptic
factors
Lecture 2 Pre- and post-synaptic molecular
mechanism underlying L-DOPA-induced dyskinesia
possible new pharmacological targets
Lecture 3 Multiple dopamine-dependent synaptic
mechanisms underlying dyskinesia in animal models
Parallel Session Pathophysiology and management
of head drop and bent spine in PD Are they
dystonia or myopathy or both?
Lecture 1 Myopathy causing camptocormia in
idiopathic Parkinson's disease
Lecture 2 Camptocormia pathogenesis,
classification, and response to therapy
Lecture 3 Dropped head syndrome in Parkinson's
disease
13
Day 3 Parallel Session I
Workshop 1 What you need to know about DBS
Selection, side effects, and new device
development
Workshop 2 Is PD an accelerated form of aging?
Workshop 3 Pain in PD
Workshop 4 Speech and Parkinsons
14
Day 3 Parallel Session II
Parallel Session Freezing and falls
Lecture 1 Freezing- Underlying mechanisms and
the role of cueing
Lecture 2 Why do persons with PD fall? Does
treatment help to reduce falling?
Lecture 3 The benefits of exercise in reducing
falling in PD
Parallel Session Promising approaches to
identify and validate biomarkers
Lecture 1 What are biomarkers and why do we need
them?
Lecture 2 Update on unbiased methodologies to
identify biomarkers
Lecture 3 Emerging biomarkers
Parallel Session Drug development challenges
from the pharmaceutical industry, regulatory
agencies, and patient protection organizations
perspective
Lecture 1 Drug development challenges-Pharmaceuti
cal industry perspective
Lecture 2 Drug development challenges - A
regulatory perspective
Lecture 3 Drug development challenges-Patient
protection agency perspective
Parallel Session How should levodopa induced
dyskinesia be managed today?
Lecture 1 Recognizing the subtypes and assessing
severity of dyskinesia and the clinical impact
Lecture 2 Current management of LID medical
and surgical
Lecture 3 Future Management of LID Whats in
the pipeline?
15
Day 3 Parallel Session II
Workshop 1 The role of people with Parkinson's
in the research process How are they prepared
and what can they do?
Workshop 2 Which physical and mental exercises
are good for people with Parkinsons?
Workshop 3 Parkinson's and Mood Changes
Depression, Apathy and Anxiety